Inventor · disambiguated record
Natalie Bezman
Also filed as: BEZMAN NATALIE · BEZMAN NATALIE A
5 granted patents·8 pending applications·8 citations·filing 2015–2025
73Inventor score
Top patents by PatentIndex Score
13 records- 0190US12077584B2Methods of treating HLA-E-expressing cancers by administering antibodies which bind human natural killer cell inhibitory receptor group 2A (NKG2A)BRISTOL MYERS SQUIBB CO·Filed 2022·Granted Sep 3, 2024·1 cites·76 claims
- 0288US11274150B2Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodiesBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Mar 15, 2022·2 cites·113 claims
- 0387US12037407B2Immune cells having co-expressed shRNAS and logic gate systemsARSENAL BIOSCIENCES INC·Filed 2023·Granted Jul 16, 2024·2 cites·71 claims
- 0483US11242393B2Antibodies against MICA and/or MICB and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Feb 8, 2022·3 cites·19 claims
- 0583US2025101100A1Anti-nkg2a antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 0678US11981734B2Nucleic acid molecules encoding antibodies which bind natural killer cell inhibitory receptor group 2A protein (NKG2A)BRISTOL MYERS SQUIBB CO·Filed 2022·Granted May 14, 2024·0 cites·163 claims
- 0772US2024309106A1Immune cells having co-expressed shrnas and logic gate systemsARSENAL BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 0865US2025049854A1Cells comprising a suppressor of gene expression and/or a syntheticpathway activator and/or an inducible payloadARSENAL BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 0963US2022281980A1Antibodies against mica and/or micb and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 1060US2025250350A1Immune cells having co-expressed shrnas and logic gate systemsArsenal Biosciences·Filed 2025·Application pending·0 cites
- 1152US2022235380A1Immune cells having co-expressed shrnas and logic gate systemsARSENAL BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 1241US2025215438A1Immune cells having co-expressed tgfbr shrnasARSENAL BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 1337US2017355768A1Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)BRISTOL MYERS SQUIBB CO·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →